Introduction: Gender-affirming hormone therapy (GAHT) is a cornerstone of gender-affirming care for transgender and gender diverse (TGD) patients, with a direct biological role on bone metabolism. However, a paucity of data describes how GAHT influences fracture rate over time. The study's primary objective was to describe the 5-year all-cause fracture incidence rate (IR) among TGD patients initiating estrogen-based GAHT (E-GAHT) or testosterone-based GAHT (T-GAHT), compared with TGD patients not using GAHT (non-GAHT).
View Article and Find Full Text PDFBackground During the 2020 COVID outbreak, telemedicine usage rates skyrocketed. We investigated the effect of telemedicine availability and demographic factors on orthopedic oncologist ratings and review rates. We also investigated patient-reported positive and negative experiences on www.
View Article and Find Full Text PDFInt J Environ Res Public Health
October 2024